TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27886382
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule daily for 6 weeks)
Study: 19553407
Drug: NB‐UVB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB plus oral vitamin E (group A)
Study: 17684214
Drug: Glutamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.25 mg/kg body weight) administered orally twice daily for 5 months
Study: 17684214
Drug: Placebo (isonitrogenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isonitrogenous, isoenergetic mix of nonessential amino acids) administered orally twice daily for 5 months
Study: 9118772
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg QAM)
Study: 3520622
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose insulin infusion clamp study (8mU/M2/min)
Study: 3520622
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose insulin infusion clamp study (40mU/M2/min)
Study: 22650119
Drug: Acupoint thread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint thread embedding combined with western medicine routine therapy
Study: 22650119
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy group (western medicine routine therapy)
Study: 22990319
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.3 or 0.5 mg)
Study: 9695060
Drug: Workers with
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workers with urine mercury concentration between 51 and 150 micrograms l-1
Study: 9695060
Drug: Workers with
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workers with urine mercury concentrations above 150 micrograms l-1
Study: 8083550
Drug: Puvasol in
Normalized name: docusate sodium / sennosides, USP Oral Tablet [Purgasol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puvasol in combination with topical tar therapy
Study: 23650416
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg daily plus entinostat 5 mg once per week (EE)
Study: 19359813
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of bepridil
Study: 19359813
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of bepridil
Study: 16371522
Drug: Self-hypnotic relaxation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-hypnotic relaxation
Study: 12166555
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg)
Study: 11062381
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (NHT) using an LHRH analog (goserelin) plus flutamide for a period of 3 months
Study: 19240996
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (NHT)
Study: 9066598
Drug: EPI alone
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI alone (120 mg/m2 x 3)
Study: 9066598
Drug: EPI +
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI + ICRF‐187 (1000 mg/m2)
Study: 9066598
Drug: EPI +
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI + C0Q10 (50 mg/day)
Study: 8373608
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium (4 mg/kg) and succinylcholine (1 mg/kg)
Study: 28230639
Drug: Early discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early discontinuation of CNI therapy after introduction of an mTOR inhibitor
Study: 28230639
Drug: mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor initiation in maintenance patients
Study: 23578724
Drug: Mitomycin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin (12 mg/m² on day 1) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Study: 23578724
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m² on days 1 and 29) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Study: 23578724
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14)
Study: 17264222
Drug: HD+AA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD+AA (2 h of hemodialysis with amino acid infusion)
Study: 17264222
Drug: HD-O (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-O (2 h of hemodialysis without amino acid infusion)
Study: 11560566
Drug: Clozapine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (50 mg)
Study: 9713556
Drug: Tibolone (TIB)
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (TIB) 2.5 mg/day (n = 28)
Study: 9713556
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26)
Study: 9713556
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol patch (TTS) releasing 50 micrograms/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20)
Study: 26016697
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioural therapy (CBT) for insomnia (in addition to treatment as usual)
Study: 28888927
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioural therapy (CBT) for insomnia
Study: 23032417
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (TIV), two doses 1 month apart
Study: 20919540
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy based on routine hemodynamic parameters (blood pressure, heart rate, central venous pressure, daily fluid balance)
Study: 17075113
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF)
Study: 7732331
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg before breakfast)
Study: 9005122
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg before bedtime)
Study: 22491410
Drug: Patching therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching therapy (1 hour per day per month of age until 8 months, then 50% of waking hours thereafter)
Study: 19449344
Drug: Danshen dripping
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen dripping pill (DDP)
Study: 19449344
Drug: Non-DDP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-DDP treatment (Control)
Study: 11208681
Drug: losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (25 mg/d)
Study: 3628831
Drug: Apomorphine HCl
Normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine HCl (0.25, 0.5, 0.75, 1.0 mg sc)
Study: 3628831
Drug: Bromocriptine (2.5-3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5-3.75 mg/d po)
Study: 1300301
Drug: 0.03% Flurbiprofen‐Na+
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% Flurbiprofen‐Na+ eye drops 1/2 hourly starting two hours before surgery
Study: 6543134
Drug: Naftidrofuryl (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (100-200 mg/day for 7-14 days)
Study: 31622058
Drug: Allokin-alpha therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allokin-alpha therapy (9 injections of s/c, 1.0 mg every other day)
Study: 31622058
Drug: Valtrex (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valtrex (500 mg x 2 times/day, by mouth for two months)
Study: 31168175
Drug: Allogeneic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic platelet gel
Study: 24274958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (observed without treatment)
Study: 23620599
Drug: Oxytocin inhalation
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin inhalation
Study: 16238894
Drug: GAL-ER 24
Normalized name: Galfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAL-ER 24 mg qd (fasted)
Study: 16238894
Drug: GAL-ER 24
Normalized name: Galfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAL-ER 24 mg qd (fed)
Study: 16238894
Drug: GAL-IR 12
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAL-IR 12 mg bid (fasted)
Study: 7769096
Drug: Vanadyl sulfate
Normalized name: Vanadyl Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanadyl sulfate (VS) 100 mg/d for 3 weeks
Study: 2311809
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intramuscular bromocriptine retard
Study: 2311809
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intramuscular bromocriptine retard
Study: 2311809
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intramuscular bromocriptine retard
Study: 2311809
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intramuscular bromocriptine retard
Study: 31795482
Drug: AAT-120 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAT-120 (60 or 120 mg/kg)
Study: 31795482
Drug: AAT-60 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAT-60 (60 or 120 mg/kg)
Study: 29779416
Drug: Indacaterol/Glycopyrronium (110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/Glycopyrronium (110/50 μg once daily)
Study: 29779416
Drug: Triple Therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Therapy (tiotropium [18 μg] once daily plus salmeterol/fluticasone propionate [50/500 μg] twice daily)
Study: 26681262
Drug: Oxytocin treatment
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin treatment spray (placebo)
Study: 26681262
Drug: Serotonin treatment
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin treatment spray (placebo)
Study: 17234506
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing 460 mg of omega-3 polyunsaturated fatty acids and/or 580 mg of soluble fibers
Study: 16847182
Drug: Nasal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal treatment with amphotericin B for 8 weeks
Study: 14676082
Drug: Etanercept, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept, 25 mg, subcutaneously twice a week for 24 weeks
Study: 11030848
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion of 40 mg/kg
Study: 8796393
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of i.v. nicardipine
Study: 6722081
Drug: Nutrient-dense supplement
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient-dense supplement (A)
Study: 29763373
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose challenge (OGC, 50 g glucose)
Study: 27956074
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual, commenced immediately after discharge.
Study: 27956074
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual.
Study: 25480457
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of prognostic data as frequencies (e.g., 1 in 50)
Study: 23782653
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care arm therapy.
Study: 23782653
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care arm therapy
Study: 18245179
Drug: olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine plus metformin (15 mg/day + 750 mg/day)
Study: 18245179
Drug: olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine plus placebo (15 mg/day + placebo)
Study: 18245179
Drug: olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine plus metformin
Study: 12682319
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean daily dose of 2.5 +/- 0.85)
Study: 8969678
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of prostaglandin analogues to support gastric homeostasis
Study: 1643676
Drug: Midazolam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.75 mg.kg‐1
Study: 1643676
Drug: Midazolam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1.0 mg.kg‐1
Study: 6442057
Drug: Auranofin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (oral gold salt)
Study: 6442057
Drug: Sodium aurothiomalate
Normalized name: Sodium aurothiomalate
DrugBank: Sodium aurothiomalate (DB09276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium aurothiomalate (parenteral gold salt)
Study: 6442057
Drug: Other baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other baseline antirheumatoids (D-penicillamine, antimalarials)
Study: 31978611
Drug: Intravenous ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ribavirin for confirmed LF patients
Study: 31978611
Drug: Standardized supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized supportive care and biological monitoring
Study: 31171878
Drug: Triplet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet therapy (dabrafenib, trametinib, pembrolizumab)
Study: 31171878
Drug: Doublet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet therapy (dabrafenib, trametinib, placebo)
Study: 24628035
Drug: TA-8995 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-8995 (5, 10, 25, 50, 100, 150 mg single doses; 1, 2.5, 10, 25 mg once daily for 21-28 days)
Study: 24628035
Drug: TA-8995 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-8995 (2.5 to 25 mg once daily)
Study: 19200119
Drug: Treatment x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment x day interactions
Study: 3533567
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg capsules of nifedipine
Study: 3533567
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsules of nifedipine
Study: 3533567
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg capsules of nifedipine
Study: 3533567
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablets of nifedipine
Study: 3533567
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of nifedipine
Study: 3533567
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 20 mg capsules and 20 mg tablets
Study: 3533567
Drug: Nifedipine tablets
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine tablets
Study: 31778632
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg IV)
Study: 31778632
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg IV)
Study: 28420629
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg intravenous at induction of anaesthesia)
Study: 25606834
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (5 mV, 650 nm, 20 minutes a day, 5 days a week for 4 weeks)
Study: 25606834
Drug: Inactive dummy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive dummy treatment (placebo)
Study: 24307207
Drug: zuclopenthixol at
Normalized name: zuclopenthixol
DrugBank: Zuclopenthixol (DB01624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: zuclopenthixol at a dose of 2-20 mg/d
Study: 11598604
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment (28 IU/m2/wk)
Study: 7575274
Drug: Decapinol mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapinol mouthwash 2 mg/mL
Study: 2105988
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) administration
Study: 6157203
Drug: Econazole nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole nitrate 150 mg per day for 3 days
Study: 6157203
Drug: Econazole nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole nitrate 50 mg per day for 14 days
Study: 23955709
Drug: 25,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25,000 IU retinyl palmitate capsule daily for 6 months
Study: 23955709
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily for 6 months
Study: 19216763
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) consisting of mobilisations, exercise therapy for the cervical and thoracic spine, and postural correction.
Study: 17646620
Drug: Rivastigmine patches
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patches
Study: 9000318
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment (traditional antipsychotic drugs)
Study: 1361435
Drug: Alfuzosin (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (alpha 1-receptor-blocking compound)
Study: 6437263
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg D2343
Study: 6437263
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terbutaline
Study: 20237029
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (100 mg every 4 h for 6 days)
Study: 19000845
Drug: Computerized educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized educational session and provision of 200 folate tablets
Study: 1423181
Drug: Ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg)
Study: 14634409
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg, adjustable to 100 or 25 mg)
Study: 10995004
Drug: 9-cis retinoic
Normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-cis retinoic acid (9CRA) at 60 mg/m2 daily for 1 week, then escalating to 100 mg/m2 during the second week, up to a maximum of 140 mg/m2 for a planned duration of 48 weeks.
Study: 1469177
Drug: Selective Decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Decontamination of the Digestive Tract (SDD) with Cefotaxime i.v. (6 g/day) for the first four days and Polymyxin E, Tobramycin and Amphotericin B at the oropharyngeal and gastrointestinal level throughout the whole stay
Study: 30101278
Drug: Morphine (Control)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (Control)
Study: 29540661
Drug: N-acetylcysteine 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 900 mg/day for 7 days before surgery
Study: 26963952
Drug: Older men
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older men with age-related low T levels (4% positive for antipituitary antibodies)
Study: 26963952
Drug: Healthy young
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy young and older eugonadal men (0% positive for antipituitary antibodies)
Study: 24687829
Drug: Bevacizumab-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-containing therapy (BEV-CT)
Study: 22574084
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with free iron tablets (A group)
Study: 16200253
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (5 g/day for 28 days)